Answers are grounded in this paper and cite their sources.
This study aimed to investigate the pharmacokinetics of curcumin (CUR) and its anti-cancer activity against B16F10 cell in mice using CUR-and pluronic P85 (PP85)-loaded mesoporous silica nanoparticles.CUR was incorporated into mesoporous nanosilicate (SMB7) using a solvent extraction method, and PP85 was also loaded into SMB7 using a freeze-drying method.The final formulation, CUR-PP85-SMB7, was optimized at a ratio of 1:2:4 (w/w).The solubility and release profile of CUR from CUR-PP85-SMB7 were greatly improved compared with CUR alone.The plasma concentrations of CUR were also increased in mice administered CUR-PP85-SMB7 intraperitonially at a dose of 5 mg CUR compared with equivalent dose of standalone CUR.Moreover, tumor growth was inhibited through the repeated intraperitonial administration of CUR-PP85-SMB7 (20 mg CUR equivalent/kg for 7 days) in B16F10 melanoma-bearing mice, and the inhibition was even more marked than that of the CUR-SMB7 group with equivalent dose and the same dose in the CUR-only treatment group.The CUR concentration in tumor tissues at 4 h after the last CUR dose was the highest in the CUR-PP85-SMB7 group, and comparable in the CUR-SMB7 and CUR-only groups.These findings suggest that the P-glycoprotein (P-gp) inhibitory effect of PP85 from CUR-PP85-SMB7 can increase the CUR accumulation in B16F10 melanoma tissues and improved the anti-cancer efficacy.In conclusion, the improved pharmacokinetic properties and anti-cancer activity of CUR could be achieved by preparing CUR-and PP85-loaded mesoporous silica nanoparticles.Incorporation of PP85, a surfactant that has P-gp inhibitory effect, into SMB7 together with CUR potentiated the anti-cancer effect of CUR in B16F10 melanoma-bearing mice by increasing the release and the intratumor concentration of CUR.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: